Efficacy and landscape of Covid-19 vaccines: a review article.
Rev Assoc Med Bras (1992)
; 67(3): 474-478, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-1381318
ABSTRACT
INTRODUCTION:
The rapid advance of Coronavirus disease 2019 (Covid-19) has led to the incessant search for therapeutic and prophylactic measures to fight the pandemic. Because it is a viral infection, the safest long-term prophylactic form, in addition to social distance and hygiene, is the vaccine.OBJECTIVE:
Thus, this study aimed at conducting a review of the efficacy and landscape of Covid-19 vaccines.METHODS:
The following electronic databases were used MEDLINE via PubMed, SCIELO, LILACS, NEJM, and Clinical Trials. Our study includes the 7 vaccines (phase 3) that reported an efficacy rate for Covid-19, including characteristics inherent to each one of them.RESULTS:
Preliminary studies have shown that, although an efficacy ≥70% is necessary to eliminate the infection, a prophylactic vaccine with efficacy <70% will still have an important impact and can contribute to the elimination of the virus, provided that appropriate measures of social distancing remain.CONCLUSIONS:
The effectiveness of the vaccines obtained in this study varied between 50.38 and 95%, data that may represent a reduction in serious cases, hospitalizations, sequels, and deaths caused by Covid-19, respecting the panorama presented in this article.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
COVID-19
Type of study:
Prognostic study
/
Reviews
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Rev Assoc Med Bras (1992)
Year:
2021
Document Type:
Article
Affiliation country:
1806-9282.20210073
Similar
MEDLINE
...
LILACS
LIS